| Cynthia Patrice Valle, CNM | |
|
4660 Kenmore Avenue Suite 902, Alexandria, VI 22304 | |
| (703) 370-4300 | |
| (703) 370-1683 |
| Full Name | Cynthia Patrice Valle |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 4660 Kenmore Avenue Suite 902, Alexandria, Virgin Island |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992917140 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | 0024118896 (Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Cynthia Patrice Valle, CNM 116 Ingle Place, Alexandria, VA 22304 Ph: (703) 823-0047 | Cynthia Patrice Valle, CNM 4660 Kenmore Avenue Suite 902, Alexandria, VI 22304 Ph: (703) 370-4300 |
News Archive
The Journal of the American Medical Association (JAMA) has announced that a study to be published in the June 22/29 issue found that a new vaccine against whooping cough is effective in teens and adults, carriers of the contagious respiratory disease so dangerous to infants.
The recent localized government handout of samples of potassium iodide has sky-rocketed sales for online merchant Nukepills.com. Recent retail orders of Iosat(TM) Potassium Iodide have increased by almost 400% and wholesale orders to vendors and medical facilities have surged as well for the authorized national distributor.
EpiCept Corporation announced today that it has entered into an exclusive commercialization agreement for Ceplene® (histamine dihydrochloride) with Meda AB, a leading international specialty pharmaceutical company based in Stockholm. Ceplene is EpiCept's novel therapy approved in the European Union with orphan drug status for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first remission.
Mice, rats, worms, flies, and yeast all live longer on a low-calorie diet, which also seems to protect mammals against cancer and other aging-related diseases.
VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like receptor 8 (TLR8) immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of motolimod (VTX-2337) when administered in combination with pegylated liposomal doxorubicin (PLD) for the treatment of women with ovarian cancer whose disease has progressed on or recurred after platinum-based chemotherapy.
› Verified 9 days ago